BioCryst Pharmaceuticals is getting out of the business of inventing its own drugs.
According to Endpoints News, the company is winding down its internal drug discovery work and plans to look for future drug programs externally instead. As part of that shift, Endpoints reports, BioCryst announced a plan to discontinue its internal discovery programs and will close its research facility in Alabama.
Drug discovery is the earliest, riskiest stage of the pharmaceutical pipeline — the painstaking lab work of finding new molecules that might one day become medicines. By stepping back from doing that in-house, BioCryst is signaling it would rather acquire or license promising candidates that others have already developed than fund the slow, expensive hunt itself.
The move also carries a human cost: shutting the Alabama site means BioCryst is consolidating its operations and stepping away from a physical research footprint, according to Endpoints News.
Why it matters: when a drugmaker stops discovering its own molecules and turns to outside deals to fill its pipeline, it reflects a broader industry trend of trading the gamble of homegrown science for the speed of buying innovation — a bet that reshapes where the next generation of medicines actually comes from.